Industry
Biotechnology
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Loading...
Open
5.76
Mkt cap
2M
Volume
805K
High
5.95
P/E Ratio
-0.01
52-wk high
399.60
Low
4.08
Div yield
N/A
52-wk low
4.08
Portfolio Pulse from
December 12, 2024 | 6:00 pm
Portfolio Pulse from
November 22, 2024 | 2:00 pm
Portfolio Pulse from
November 20, 2024 | 2:00 pm
Portfolio Pulse from
November 07, 2024 | 1:30 pm
Portfolio Pulse from Benzinga Insights
October 29, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 6:34 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 12:08 pm
Portfolio Pulse from Avi Kapoor
October 23, 2024 | 1:50 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.